Tirzepatide in the Treatment of Endometrial Cancer
NCT07605247 on ClinicalTrials.gov · last registry update 2026-05-22
A small phase 2 — 30 participants, against a typical 110. Due to report January 2028, alongside 25 other tracked readouts that quarter. Primary outcome, as filed: Quality of Life Quality of life will be measured through PROMs at the time points listed below for explorative purposes. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for cancer — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- NOT_YET_RECRUITING
- Phase
- P2
- Drug
- tirzepatideMounjaro, Zepbound
- Sponsor
- Rutgers, The State University of New Jersey
- Sponsor type
- Other
- Enrollment
- 30
- Started
- 2026-06-01
- Primary completion
- 2028-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Quality of Life Quality of life will be measured through PROMs at the time points listed below for explorative purposes.
Conditions studied
Endometrial Cancer
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.